TERVEYSTALO OYJ |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.825 EUR | -1.40% |
|
+0.91% | +14.21% |
| May. 30 | Terveystalo Plc Appoints Petra Gräsbeck as SVP, Communications and Public Affairs and Member of the Executive Team | CI |
| Apr. 26 | Transcript : Terveystalo Oyj, Q1 2024 Earnings Call, Apr 26, 2024 |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company has a low valuation given the cash flows generated by its activity.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +15.63% | 1.23B | B- | ||
| -23.96% | 15.44B | B+ | ||
| -2.70% | 11.7B | B | ||
| +2.65% | 11.58B | B+ | ||
| +0.07% | 10.12B | B+ | ||
| +25.28% | 8.42B | B | ||
| -7.87% | 7.18B | A- | ||
| +6.74% | 6.76B | B- | ||
| +1.97% | 6.08B | D | ||
| -3.14% | 4.33B | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- TTALO Stock
- Ratings Terveystalo Oyj
